Skip to main content

Table 3 Relationships between demographic, clinical characteristics, and stigma

From: Validity and reliability of the Persian version of Recce stigma scale in people with multiple sclerosis and its impact on quality of life

Variables (Mean±SD)

Stigma

p-value

Psychological effects

p-value

Physical effects

p-value

Sex

 

0.608

 

0.076

 

0.286

 Female

26.24±3.79

 

22.16±4.86

 

53.1±9.14

 

 Male

26.56±4.06

 

23.66±6.00

 

54.8±11.22

 

Marital

 

0.137

 

0.814

 

0.610

 Single

25.49±3.9

 

22.15±5.94

 

52.39±10.24

 

 Married

26.55±3.8

 

22.7±4.94

 

53.94±9.33

 

 Divorced

27.66±3.93

 

22.55±5.17

 

54.33±13.02

 

Education

 

0.353

 

0.175

 

0.465

 Elementary

28.2±4.81

 

23.2±4.91

 

54.2±10.08

 

 Cycle

26.65±3.46

 

24.85±5.47

 

52.5±12.58

 

 Diploma

25.68±3.79

 

21.94±5.16

 

52.9±9.5

 

 Bachelor

26.78±4.09

 

22.88±4.98

 

55.18±8.74

 

 Upper than bachelor

26.39±3.34

 

21.43±5.61

 

51.47±10.59

 

Job State

 

0.215

 

0.091

 

0.03

 Employed

26.68±4.01

 

23.21±5.54

 

55.66±10.31

 

 Unemployed

26±3.69

 

21.95±4.83

 

51.6±8.76

 

Treatment

 

0.841

 

0.434

 

0.632

 No treatment

 Rituximab

 IFN-B1a

 Fingolimod

 Ocrelizumab

 DMF

 Glatiramer acetate

 IFN-B1b

 Fampridine

 Teriflunomide

26.3±2.31

26.13±4.04

26.9±5.11

25.07±1.75

24.5±4.35

26.05±2.71

26.5±0.57

26.25±3.37

28.5±3.69

26.78±3.91

 

22.1±5.15

22.27±5.56

22.06±5.65

20.76±3.53

20.5±4.35

22.66±4.37

27.75±4.64

22.75±5.82

23±4.39

23.96±4.98

 

53.8±7.98

52.55±9.38

51.69±10.8

50.84±5.69

53.75±4.64

55.61±9.17

56.25±4.57

56.62±8.97

56.5±14.36

53.55±9.73

 
  1. DMF: Dimethyl fumarate, IFN: Interferon. Significant p-value is in bold